155 related articles for article (PubMed ID: 38764827)
1. Loss of heterozygosity for chromosomes 16q in Wilms tumors predicts outcomes: A meta-analysis.
Song YH; Li WL; Yang Z; Gao Y; Feng ZP
World J Gastrointest Oncol; 2024 May; 16(5):2159-2167. PubMed ID: 38764827
[TBL] [Abstract][Full Text] [Related]
2. Association between loss of heterozygosity of chromosome 16q and survival in Wilms' tumor: A meta-analysis.
Bu Q; He H; Fan D; Lyu J; Pan Z; You H
Pathol Res Pract; 2018 Nov; 214(11):1772-1777. PubMed ID: 30143352
[TBL] [Abstract][Full Text] [Related]
3. Loss of heterozygosity on chromosome 16q increases relapse risk in Wilms' tumor: a meta-analysis.
Pan Z; He H; Tang L; Bu Q; Cheng H; Wang A; Lyu J; You H
Oncotarget; 2017 Sep; 8(39):66467-66475. PubMed ID: 29029528
[TBL] [Abstract][Full Text] [Related]
4. Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG).
Park JE; Noh OK; Lee Y; Choi HS; Han JW; Hahn SM; Lyu CJ; Lee JW; Yoo KH; Koo HH; Jeong SY; Sung KW
Cancer Res Treat; 2020 Apr; 52(2):438-445. PubMed ID: 31505910
[TBL] [Abstract][Full Text] [Related]
5. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
[TBL] [Abstract][Full Text] [Related]
7. [Correlation of 1p/16q loss of heterozygosity and 1p gain with clinicopathological characteristics and prognosis in Wilms tumor].
Jia C; Yao XF; Zhang M; Guan XX; Wang JW; Song HC; He LJ
Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):257-263. PubMed ID: 38433053
[No Abstract] [Full Text] [Related]
8. Profiling Loss of Heterozygosity Patterns in a Cohort of Favorable Histology Nephroblastoma Egyptian Patients: What is Consistent With the Rest of the World.
Fawzy M; Bahanassy A; Samir A; Hafez H
Pediatr Hematol Oncol; 2015; 32(8):548-56. PubMed ID: 26390800
[TBL] [Abstract][Full Text] [Related]
9. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
Grundy PE; Telzerow PE; Breslow N; Moksness J; Huff V; Paterson MC
Cancer Res; 1994 May; 54(9):2331-3. PubMed ID: 8162576
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532.
Evageliou N; Renfro LA; Geller J; Perlman E; Kalapurakal J; Paulino A; Dix D; Eklund MJ; Murphy AJ; Romao RLP; Ehrlich PF; Varela CR; Vallance K; Fernandez CV; Dome JS; Mullen EA
Cancer; 2024 Mar; 130(5):792-802. PubMed ID: 37902955
[TBL] [Abstract][Full Text] [Related]
11. Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.
Safford SD; Goyeau D; Freemerman AJ; Bentley R; Everett ML; Grundy PE; Skinner MA
Ann Surg Oncol; 2003 Mar; 10(2):136-43. PubMed ID: 12620908
[TBL] [Abstract][Full Text] [Related]
12. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis.
Wittmann S; Zirn B; Alkassar M; Ambros P; Graf N; Gessler M
Genes Chromosomes Cancer; 2007 Feb; 46(2):163-70. PubMed ID: 17099873
[TBL] [Abstract][Full Text] [Related]
13. Association of chromosome arm 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.
Mummert SK; Lobanenkov VA; Feinberg AP
Genes Chromosomes Cancer; 2005 Jun; 43(2):155-61. PubMed ID: 15761865
[TBL] [Abstract][Full Text] [Related]
14. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.
Messahel B; Williams R; Ridolfi A; A'hern R; Warren W; Tinworth L; Hobson R; Al-Saadi R; Whyman G; Brundler MA; Kelsey A; Sebire N; Jones C; Vujanic G; Pritchard-Jones K;
Eur J Cancer; 2009 Mar; 45(5):819-26. PubMed ID: 19231157
[TBL] [Abstract][Full Text] [Related]
15. Variant profiles of genes mapping to chromosome 16q loss in Wilms tumors reveals link to cilia-related genes and pathways.
Kitamura E; Cowell JK; Chang CS; Hawthorn L
Genes Cancer; 2020 Dec; 11(3-4):137-153. PubMed ID: 33488951
[TBL] [Abstract][Full Text] [Related]
16. Allelic loss of chromosome 16q in endometrial cancer: correlation with poor prognosis of patients and less differentiated histology.
Kihana T; Yano N; Murao S; Iketani H; Hamada K; Yano J; Murao S; Iketani H; Hamada K; Yano J; Matsuura S
Jpn J Cancer Res; 1996 Nov; 87(11):1184-90. PubMed ID: 9045949
[TBL] [Abstract][Full Text] [Related]
17. Characterization of regions of chromosomes 12 and 16 involved in nephroblastoma tumorigenesis.
Austruy E; Candon S; Henry I; Gyapay G; Tournade MF; Mannens M; Callen D; Junien C; Jeanpierre C
Genes Chromosomes Cancer; 1995 Dec; 14(4):285-94. PubMed ID: 8605117
[TBL] [Abstract][Full Text] [Related]
18. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor.
Mason JE; Goodfellow PJ; Grundy PE; Skinner MA
J Pediatr Surg; 2000 Jun; 35(6):891-6; discussion 896-7. PubMed ID: 10873032
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour.
Grundy RG; Pritchard J; Scambler P; Cowell JK
Br J Cancer; 1998 Nov; 78(9):1181-7. PubMed ID: 9820177
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
Grundy P; Telzerow P; Moksness J; Breslow NE
Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
